GSK joins Manufacture 2030 to tackle ambitious sustainability targets

Manufacture 2030 are thrilled to announce our partnership with GlaxoSmithKline plc.

GSK will be using the Manufacture 2030 platform and service, which means suppliers will be able to submit environmental data to GSK. Suppliers will also be able to access a wealth of best practice actions, expert advice and enriching content all aimed at helping them to reduce their carbon footprint, while making their processes more resource and cost efficient for them.

The new partnership between Manufacture 2030 and GSK launched in late October 2021 with an initial group of high impact direct, in-direct and co-manufacturers. The programme is set to expand to a wider group of suppliers in phases through 2022 and beyond, enabling GSK to progress towards the bold climate and nature commitments they have made.

GSK is a science-led global healthcare company, which wants to play its part in protecting and restoring the planet’s health – to protect and improve people’s health. GSK has made a commitment, by 2030 to have a net zero impact on climate and a net positive impact on nature across its entire value chain.

This announcement comes as world leaders meet in Glasgow for COP26, which is set to be a defining moment in the global fight against climate change. To help drive the necessary net zero impact on climate and net positive impact on nature across the GSK’s supply chain, at the required speed and scale, GSK have selected Manufacture 2030’s unique platform and support services.

GSK’s Global Vice President for Sustainability, Claire Lund, commented, “GSK is a science-led company, and the science on climate is clear – we need to act decisively and collectively. We know that protecting and restoring the planet’s health is fundamental to protecting and improving people’s health. We also know that we cannot achieve our goals as GSK alone and that collaboration with our suppliers, as well as the wider life sciences sectors, will be critical. As such, we are delighted to be partnering with Manufacture 2030 to help us engage with other healthcare companies who are on this journey, and to support our suppliers in reducing their carbon emissions in line with our targets.”

Martin Chilcott, CEO at Manufacture 2030, added, “We are very proud to have been selected by GSK to support them in hitting their ambitious climate and nature targets. GSK’s history as a leader on environmental sustainability, and their new partnership with Manufacture 2030, shows they are committed to not only measuring environmental impacts, but proactively taking steps to reduce them as well. We are confident that the many features and insights available in our platform will enable them to do this, creating real and meaningful value for both GSK and their suppliers.”

GSK joins Reckitt and Bayer in utilising Manufacture 2030 to help them reduce their Scope 3 emissions and hit bold carbon targets with greater confidence.